Benzinga | Sep 29, 2020 06:01AM EDT

Cantor Fitzgerald Initiates Coverage On Zentalis Pharmaceuticals with Overweight Rating, Announces Price Target of $44

Cantor Fitzgerald analyst Eliana Merle initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Overweight rating and announces Price Target of $44.